Back to Search
Start Over
Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma
- Source :
- Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100631- (2022)
- Publication Year :
- 2022
- Publisher :
- Elsevier, 2022.
-
Abstract
- Objectives: The prognosis of patients presenting with stage IVB uterine serous carcinoma (USC) remains extremely poor, with a reported 5-year survival of 1 cm. Progression free survival (PFS) and overall survival (OS) analysis was performed using Kaplan-Meier estimates. Multivariate analysis (MVA) was performed using Cox proportional hazards model. Results: Final analysis included 68 patients. There was no difference in the frequency of treatment delays between regimens (p = 0.832). 96% of patients received platinum-based chemotherapy. There was no difference in the age (p = 0.227), race (p = 0.936), type of radiotherapy (p = 0.852) or chemotherapy regimen received (p = 0.996) between R1 and R2 cohorts. The median PFS for all patients was 8 months and the median OS was 13 months. Cytoreduction to R1 was associated with a median PFS of 9 months, compared to R2 with a median PFS of 4 months (p
Details
- Language :
- English
- ISSN :
- 24682942
- Volume :
- 33
- Issue :
- 100631-
- Database :
- Directory of Open Access Journals
- Journal :
- Cancer Treatment and Research Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.4eaf368675c342208336762000acb401
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.ctarc.2022.100631